<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font24 { font-size : 24; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; }</style>
 <body>
  <p>
   <span class="font30">the </span>
   <span class="font24">and </span>
   <span class="font16">with </span>
   <span class="font14">[]. </span>
   <span class="font14">for </span>
   <span class="font13">that </span>
   <span class="font12">The </span>
   <span class="font12">patients </span>
   <span class="font12">COVID- </span>
   <span class="font12">treatment </span>
   <span class="font12">viral </span>
   <span class="font12">virus </span>
   <span class="font12">have </span>
   <span class="font11">drug </span>
   <span class="font11">severe </span>
   <span class="font11">clinical </span>
   <span class="font11">has </span>
   <span class="font11">are </span>
   <span class="font11">SARS-CoV- </span>
   <span class="font11">cell </span>
   <span class="font11">may </span>
   <span class="font11">antiviral </span>
   <span class="font11">been </span>
   <span class="font11">coronavirus </span>
   <span class="font11">respiratory </span>
   <span class="font11">was </span>
   <span class="font11">infection </span>
   <span class="font11">ACE </span>
   <span class="font11">against </span>
   <span class="font11">acute </span>
   <span class="font11">{background </span>
   <span class="font11">combination </span>
   <span class="font11">lung </span>
   <span class="font11">protein </span>
   <span class="font10">human </span>
   <span class="font10">from </span>
   <span class="font10">host </span>
   <span class="font10">including </span>
   <span class="font10">influenza </span>
   <span class="font10">margin </span>
   <span class="font10">other </span>
   <span class="font10">syndrome </span>
   <span class="font10">also </span>
   <span class="font10">cells </span>
   <span class="font10">enzyme </span>
   <span class="font10">inhibits </span>
   <span class="font10">its </span>
   <span class="font10">{border-style </span>
   <span class="font10">RNA </span>
   <span class="font10">[,]. </span>
   <span class="font10">study </span>
   <span class="font10">px;} </span>
   <span class="font10">replication </span>
   <span class="font10">#ffffff;} </span>
   <span class="font10">drugs </span>
   <span class="font10">potential </span>
   <span class="font10">response </span>
   <span class="font10">use </span>
   <span class="font10">cases </span>
   <span class="font10">disease </span>
   <span class="font10">effects </span>
   <span class="font10">inhibitor </span>
   <span class="font10">receptor </span>
   <span class="font10">therapy </span>
   <span class="font10">thus </span>
   <span class="font10">used </span>
   <span class="font10">azithromycin </span>
   <span class="font10">protease </span>
   <span class="font10">which </span>
   <span class="font10">Oral </span>
   <span class="font10">entry </span>
   <span class="font10">inhibitors </span>
   <span class="font10">reported </span>
   <span class="font10">shown </span>
   <span class="font10">trials </span>
   <span class="font10">type </span>
   <span class="font10">activity </span>
   <span class="font10">adverse </span>
   <span class="font10">effect </span>
   <span class="font10">expression </span>
   <span class="font10">novel </span>
   <span class="font10">such </span>
   <span class="font10">suggested </span>
   <span class="font10">However, </span>
   <span class="font10">active </span>
   <span class="font10">associated </span>
   <span class="font10">infected </span>
   <span class="font10">this </span>
   <span class="font10">trial </span>
   <span class="font10">via </span>
   <span class="font10">viruses </span>
   <span class="font10">Agents </span>
   <span class="font10">Ivermectin </span>
   <span class="font10">Known </span>
   <span class="font10">SARS-CoV </span>
   <span class="font10">binding </span>
   <span class="font10">during </span>
   <span class="font10">immune </span>
   <span class="font10">inflammatory </span>
   <span class="font10">into </span>
   <span class="font10">more </span>
   <span class="font10">not </span>
   <span class="font10">several </span>
   <span class="font10">through </span>
   <span class="font10">... </span>
   <span class="font10">IL- </span>
   <span class="font10">Inhibits </span>
   <span class="font10">being </span>
   <span class="font10">can </span>
   <span class="font10">expected </span>
   <span class="font10">found </span>
   <span class="font10">inhibit </span>
   <span class="font10">membrane </span>
   <span class="font10">role </span>
   <span class="font10">safety </span>
   <span class="font10">should </span>
   <span class="font10">their </span>
   <span class="font10">two </span>
   <span class="font10">virus, </span>
   <span class="font10">were </span>
   <span class="font10">Infect. </span>
   <span class="font10">Intravenous </span>
   <span class="font10">PD- </span>
   <span class="font10">This </span>
   <span class="font10">death </span>
   <span class="font10">effective </span>
   <span class="font10">efficacy </span>
   <span class="font10">elevated </span>
   <span class="font10">include </span>
   <span class="font10">increased </span>
   <span class="font10">infection, </span>
   <span class="font10">interaction </span>
   <span class="font10">lopinavir/ritonavir </span>
   <span class="font10">pulmonary </span>
   <span class="font10">reactions </span>
   <span class="font10">registered </span>
   <span class="font10">review </span>
   <span class="font10">risk </span>
   <span class="font10">spike </span>
   <span class="font10">than </span>
   <span class="font10">under </span>
   <span class="font10">(NCT). </span>
   <span class="font10">COVID-, </span>
   <span class="font10">Clinical </span>
   <span class="font10">East </span>
   <span class="font10">allergic </span>
   <span class="font10">analysis </span>
   <span class="font10">angiotensin </span>
   <span class="font10">antibody </span>
   <span class="font10">baricitinib </span>
   <span class="font10">binds </span>
   <span class="font10">but </span>
   <span class="font10">case </span>
   <span class="font10">cellular </span>
   <span class="font10">complex </span>
   <span class="font10">could </span>
   <span class="font10">due </span>
   <span class="font10">early </span>
   <span class="font10">first </span>
   <span class="font10">hydroxychloroquine </span>
   <span class="font10">injury </span>
   <span class="font10">key </span>
   <span class="font10">mechanism </span>
   <span class="font10">oseltamivir </span>
   <span class="font10">px; </span>
   <span class="font10">receptors </span>
   <span class="font10">release </span>
   <span class="font10">rheumatoid </span>
   <span class="font10">sepsis </span>
   <span class="font10">studies </span>
   <span class="font10">viruses. </span>
   <span class="font10">{font-family </span>
   <span class="font10">April </span>
   <span class="font10">FDA </span>
   <span class="font10">Health </span>
   <span class="font10">JAK </span>
   <span class="font10">Med. </span>
   <span class="font10">Middle </span>
   <span class="font10">TMPRSS </span>
   <span class="font10">[], </span>
   <span class="font10">addition </span>
   <span class="font10">after </span>
   <span class="font10">agents </span>
   <span class="font10">approved </span>
   <span class="font10">both </span>
   <span class="font10">care </span>
   <span class="font10">chloroquine </span>
   <span class="font10">currently </span>
   <span class="font10">dengue </span>
   <span class="font10">development </span>
   <span class="font10">effectiveness </span>
   <span class="font10">endocytosis </span>
   <span class="font10">epithelial </span>
   <span class="font10">font-size </span>
   <span class="font10">https://clinicaltrials.gov/ct/show/NCT </span>
   <span class="font10">hypersensitivity </span>
   <span class="font10">infection. </span>
   <span class="font10">infections </span>
   <span class="font10">interferon </span>
   <span class="font10">ivermectin </span>
   <span class="font10">kinase </span>
   <span class="font10">levels </span>
   <span class="font10">most </span>
   <span class="font10">new </span>
   <span class="font10">online: </span>
   <span class="font10">phase </span>
   <span class="font10">remdesivir </span>
   <span class="font10">renal </span>
   <span class="font10">specific </span>
   <span class="font10">surface </span>
   <span class="font10">therapies </span>
   <span class="font10">who </span>
   <span class="font10">.collab: </span>
   <span class="font10">ALT/AST </span>
   <span class="font10">Another </span>
   <span class="font10">COVID-. </span>
   <span class="font10">Engl. </span>
   <span class="font10">HCQ </span>
   <span class="font10">HIV- </span>
   <span class="font10">Interestingly, </span>
   <span class="font10">MERS-CoV </span>
   <span class="font10">Oseltamivir </span>
   <span class="font10">QTc </span>
   <span class="font10">SARS </span>
   <span class="font10">SARS-CoV-. </span>
   <span class="font10">Thus, </span>
   <span class="font10">activation </span>
   <span class="font10">all </span>
   <span class="font10">anti-inflammatory </span>
   <span class="font10">between </span>
   <span class="font10">camostat </span>
   <span class="font10">cytokine </span>
   <span class="font10">days </span>
   <span class="font10">distress </span>
   <span class="font10">double; </span>
   <span class="font10">e.g., </span>
   <span class="font10">higher </span>
   <span class="font10">important </span>
   <span class="font10">inhibiting </span>
   <span class="font10">inhibition </span>
   <span class="font10">intravenous </span>
   <span class="font10">investigation </span>
   <span class="font10">leading </span>
   <span class="font10">liver </span>
   <span class="font10">major </span>
   <span class="font10">mild </span>
   <span class="font10">monoclonal </span>
   <span class="font10">only </span>
   <span class="font10">pathway </span>
   <span class="font10">pathways </span>
   <span class="font10">plasma </span>
   <span class="font10">potent </span>
   <span class="font10">previous </span>
   <span class="font10">showed </span>
   <span class="font10">significant </span>
   <span class="font10">targeting </span>
   <span class="font10">therapeutic </span>
   <span class="font10">these </span>
   <span class="font10">treated </span>
   <span class="font10">various </span>
   <span class="font10">ANGII </span>
   <span class="font10">ATR </span>
   <span class="font10">Antiviral </span>
   <span class="font10">Baricitinib </span>
   <span class="font10">CYPA </span>
   <span class="font10">Camrelizumab </span>
   <span class="font10">Care </span>
   <span class="font10">China </span>
   <span class="font10">Currently, </span>
   <span class="font10">Janus </span>
   <span class="font10">Med../NEJMoa </span>
   <span class="font10">Non-significant </span>
   <span class="font10">Patients </span>
   <span class="font10">Remdesivir </span>
   <span class="font10">Severe </span>
   <span class="font10">Table </span>
   <span class="font10">Treatment </span>
   <span class="font10">acid </span>
   <span class="font10">addition, </span>
   <span class="font10">among </span>
   <span class="font10">angiotensin-converting </span>
   <span class="font10">available </span>
   <span class="font10">blood </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">cause </span>
   <span class="font10">critically </span>
   <span class="font10">cytokines </span>
   <span class="font10">decrease </span>
   <span class="font10">developed </span>
   <span class="font10">developing </span>
   <span class="font10">different </span>
   <span class="font10">dose </span>
   <span class="font10">either </span>
   <span class="font10">enhance </span>
   <span class="font10">events </span>
   <span class="font10">failure </span>
   <span class="font10">function </span>
   <span class="font10">further </span>
   <span class="font10">heart </span>
   <span class="font10">hospitalized </span>
   <span class="font10">humanized </span>
   <span class="font10">ill </span>
   <span class="font10">immunoglobulins </span>
   <span class="font10">included </span>
   <span class="font10">infections, </span>
   <span class="font10">investigated </span>
   <span class="font10">known </span>
   <span class="font10">lopinavir </span>
   <span class="font10">low </span>
   <span class="font10">management </span>
   <span class="font10">medications </span>
   <span class="font10">mesylate </span>
   <span class="font10">mortality </span>
   <span class="font10">patients. </span>
   <span class="font10">polymerase </span>
   <span class="font10">possible </span>
   <span class="font10">proteins </span>
   <span class="font10">rapid </span>
   <span class="font10">rate </span>
   <span class="font10">recent </span>
   <span class="font10">recently </span>
   <span class="font10">recombinant </span>
   <span class="font10">reduce </span>
   <span class="font10">reduction </span>
   <span class="font10">responses </span>
   <span class="font10">ritonavir </span>
   <span class="font10">screening </span>
   <span class="font10">see </span>
   <span class="font10">serious </span>
   <span class="font10">small </span>
   <span class="font10">solid; </span>
   <span class="font10">there </span>
   <span class="font10">tocilizumab </span>
   <span class="font10">treat </span>
   <span class="font10">tuberculosis </span>
   <span class="font10">using </span>
   <span class="font10">well </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">&amp;lt; </span>
   <span class="font10">(NCT </span>
   <span class="font10">ACEi </span>
   <span class="font10">ARB </span>
   <span class="font10">Bevacizumab </span>
   <span class="font10">ChiCTR). </span>
   <span class="font10">Chinese </span>
   <span class="font10">Clin. </span>
   <span class="font10">Drug </span>
   <span class="font10">Ebola </span>
   <span class="font10">Figure </span>
   <span class="font10">Fingolimod </span>
   <span class="font10">GIT </span>
   <span class="font10">HN, </span>
   <span class="font10">Hypersensitivity </span>
   <span class="font10">IL-, </span>
   <span class="font10">Meplazumab </span>
   <span class="font10">Moreover, </span>
   <span class="font10">PD-L </span>
   <span class="font10">Pregnancy </span>
   <span class="font10">RNA-dependent </span>
   <span class="font10">Res../j.antiviral... </span>
   <span class="font10">Respir. </span>
   <span class="font10">Rev. </span>
   <span class="font10">Ribavirin </span>
   <span class="font10">Ruxolitinib </span>
   <span class="font10">Several </span>
   <span class="font10">T-cells </span>
   <span class="font10">Virol../JVI.- </span>
   <span class="font10">Wuhan, </span>
   <span class="font10">agent </span>
   <span class="font10">agent, </span>
   <span class="font10">al. </span>
   <span class="font10">al.A </span>
   <span class="font10">analog </span>
   <span class="font10">and, </span>
   <span class="font10">another </span>
   <span class="font10">antibodies </span>
   <span class="font10">around </span>
   <span class="font10">asthenia, </span>
   <span class="font10">authors </span>
   <span class="font10">based </span>
   <span class="font10">before </span>
   <span class="font10">benefit </span>
   <span class="font10">block </span>
   <span class="font10">blocking </span>
   <span class="font10">bold </span>
   <span class="font10">broad </span>
   <span class="font10">broad-spectrum </span>
   <span class="font10">causes </span>
   <span class="font10">cells, </span>
   <span class="font10">chance </span>
   <span class="font10">clearance </span>
   <span class="font10">combined </span>
   <span class="font10">common </span>
   <span class="font10">compared </span>
   <span class="font10">computational </span>
   <span class="font10">concentration </span>
   <span class="font10">control </span>
   <span class="font10">courier; </span>
   <span class="font10">data </span>
   <span class="font10">diseases </span>
   <span class="font10">down </span>
   <span class="font10">dysfunction </span>
   <span class="font10">em; </span>
   <span class="font10">endothelial </span>
   <span class="font10">enzymes </span>
   <span class="font10">essential </span>
   <span class="font10">evidence </span>
   <span class="font10">favipiravir </span>
   <span class="font10">fusion </span>
   <span class="font10">hand, </span>
   <span class="font10">healthy </span>
   <span class="font10">high </span>
   <span class="font10">https://clinicaltrials.gov/ct/show/NCThttps://clinicaltrials.gov/ct/show/NCThttps://clinicaltrials.gov/ct/show/NCThttps://clinicaltrials.gov/ct/show/NCT </span>
   <span class="font10">immunoglobulin </span>
   <span class="font10">importin </span>
   <span class="font10">induced </span>
   <span class="font10">inflammation </span>
   <span class="font10">inhibitor. </span>
   <span class="font10">interactions </span>
   <span class="font10">interleukin- </span>
   <span class="font10">lead </span>
   <span class="font10">leads </span>
   <span class="font10">metabolism </span>
   <span class="font10">molecule </span>
   <span class="font10">multiple </span>
   <span class="font10">myocardial </span>
   <span class="font10">myocarditis </span>
   <span class="font10">neuraminidase </span>
   <span class="font10">neuropsychiatric </span>
   <span class="font10">neutralizing </span>
   <span class="font10">nuclear </span>
   <span class="font10">number </span>
   <span class="font10">organ </span>
   <span class="font10">pharmacological </span>
   <span class="font10">prevent </span>
   <span class="font10">preventing </span>
   <span class="font10">previously </span>
   <span class="font10">pro-inflammatory </span>
   <span class="font10">production </span>
   <span class="font10">proteins. </span>
   <span class="font10">pt;} </span>
   <span class="font10">rapidly </span>
   <span class="font10">reports </span>
   <span class="font10">repurposed </span>
   <span class="font10">required </span>
   <span class="font10">results </span>
   <span class="font10">ribavirin </span>
   <span class="font10">safe </span>
   <span class="font10">serine </span>
   <span class="font10">slow </span>
   <span class="font10">spread </span>
   <span class="font10">support </span>
   <span class="font10">symptoms </span>
   <span class="font10">syndrome- </span>
   <span class="font10">synthesis </span>
   <span class="font10">system </span>
   <span class="font10">target </span>
   <span class="font10">tested </span>
   <span class="font10">vascular </span>
  </p>
 </body>
</html>
